L2 Diagnostics, LLC
Publicly observedNew Haven, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | New Haven | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | L2 Diagnostics, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | GKA7VH5LFR25 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant21 Sept 2026Publicly observed
NIH SBIR/STTR award: A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (CLE)
USD 323,090.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant23 Sept 2025Publicly observed
NIH SBIR/STTR award: A vaccine targeting mosquito metabolic pathways to eradicate malaria
USD 300,065.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant23 Sept 2025Publicly observed
NIH SBIR/STTR award: A vaccine targeting mosquito metabolic pathways to eradicate malaria
USD 299,644.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant23 Sept 2025Publicly observed
NIH SBIR/STTR award: A viral vector-based vaccine to induce humoral and cellular immune protection against Powassan virus in a tick transmission model
USD 281,786.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant21 Sept 2025Publicly observed
NIH SBIR/STTR award: A Point of Care Test for Babesia microti
USD 274,710.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant21 Sept 2025Publicly observed
NIH SBIR/STTR award: A Point of Care Test for Babesia microti
USD 293,142.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: PfAg, a multivalent peptide vaccine against malaria
USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: PfAg, a multivalent peptide vaccine against malaria
USD 299,954.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant17 Jul 2024Publicly observed
NIH SBIR/STTR award: The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya
USD 299,969.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant8 Jul 2024Publicly observed
NIH SBIR/STTR award: A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor
USD 299,933.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2024Publicly observed
NIH SBIR/STTR award: Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches
USD 299,862.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2024Publicly observed
NIH SBIR/STTR award: A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens
USD 299,250.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.